C12Y 304/21098
Hepacivirin
Official title: Hepacivirin (3.4.21.98)
C12Y304/21098 (Hepacivirin) appears on 14 US grants and 26 published applications in this corpus.
Search patents in C12Y- Granted patents
- 14
- Published applications
- 26
- Assignees
- 7
- Inventors
- 43
- Latest grant
- 18 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 1 | 2 |
| 2013 | 1 | 1 |
| 2014 | 0 | 0 |
| 2015 | 1 | 1 |
| 2016 | 1 | 1 |
| 2017 | 0 | 1 |
| 2018 | 0 | 1 |
| 2019 | 0 | 2 |
| 2020 | 1 | 3 |
| 2021 | 1 | 4 |
| 2022 | 1 | 3 |
| 2023 | 2 | 2 |
| 2024 | 3 | 0 |
| 2025 | 2 | 1 |
| 2026 | 0 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Chimeric antigen receptor polypeptides and methods of using same18 Nov 2025US 12,473,344 B2The Board of Trustees of the Leland Stanford Junior University
- Chimeric antigen receptor (CAR) modulation21 Jan 2025US 12,202,863 B2Trustees of Boston University
- Programmable protein circuits in living cells23 Apr 2024US 11,965,191 B2California Institute of Technology
- RNA-based delivery systems with levels of control2 Apr 2024US 11,946,066 B2California Institute of Technology
- Rewiring aberrant cancer signaling to a therapeutic effector response with a synthetic two-component system26 Mar 2024US 11,939,609 B2The Board of Trustees of the Leland Stanford Junior University
- Chimeric Cytokine Receptors and Methods of Use8 Oct 2026US 2026/0308235 A1
- Chimeric Antigen Receptor Polypeptides and Methods of Using Same16 Apr 2026US 2026/0103504 A1The Board of Trustees of the Leland Stanford Junior University
- Chimeric antigen receptor (car) modulation31 Jul 2025US 2025/0243247 A1Trustees of Boston University
- Novel drug-controlled systems and uses thereof3 Aug 2023US 2023/0241026 A1Trustees of Boston University
- Rna-based delivery systems with levels of control22 Jun 2023US 2023/0193317 A1California Institute of Technology
Most cited
By later US patents
- HCV protease inhibitors and uses thereof11US 8,188,137 B2Avila Therapeutics, Inc. · 2012
- HCV protease inhibitors and uses thereof8US 8,524,760 B2Celgene Avilomics Research, Inc. · 2013
- HCV protease inhibitors and uses thereof7US 8,980,935 B2Celgene Avilomics Research, Inc. · 2015
- Degron fusion constructs and methods for controlling protein production3US 10,550,379 B2The Board of Trustees of the Leland Stanford Junior University · 2020
- Chimeric antigen receptor (CAR) modulation1US 11,059,864 B2Trustees of Boston University · 2021